Loading data for ACRV — first visit, this takes a few seconds.
Acrivon Therapeutics Inc. (ACRV)
NasdaqGM: ACRV
· Real-Time Price · USD
2.15
+0.07 (3.37%)
At close: Aug 27, 2026, 3:59 PM
The price, the headline numbers and the latest news, in one place.
Acrivon Therapeutics Inc. (ACRV) Stock Price, Analysis & Data
3.37% (1D)
| Bid | 1.14 |
| Market Cap | 92.13M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -74.22M |
| 1.86 | |
| -1.88 | |
| n/a | |
| -1.28 | |
| P/B (ttm) | 1.06 |
| P/S (ttm) | n/a |
| Earnings Date | Aug 14, 2025 |
| Ask | 2.06 |
| Volume | 188,253 |
| Avg. Volume (20D) | 403,229 |
| Open | 2.11 |
| Previous Close | 2.08 |
| Day's Range | 2.09 - 2.19 |
| 52-Week Range | 1.27 - 3.56 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About ACRV
Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are ...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 15, 2022
Employees 74
Stock Exchange NasdaqGM
Ticker Symbol ACRV
Website https://acrivon.com
Financial Performance
In 2025, Acrivon Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -77.91M, a decrease of -3.29%.
Financial StatementsEarnings Surprise
Acrivon Therapeutics has released their quarterly earnings on Aug 12, 2026:
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -0.43 exceeds estimates by 0.07, with 21.82% YoY growth.
Acrivon Therapeutics Inc. is scheduled to release its earnings on Aug 14, 2025, after market closes.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2